Topical Tranexamic Acid to Reduce Seizures in Cardiac Surgery

Dr. Andre Lamy on behalf of DEPOSITION Investigators Population Health Research Institute McMaster University, Hamilton, Canada

Canadian Institute of Health Research

ACCZQ



Research Institute EALTH THROUGH KNOWLEDGE



Disclosure

• None



Background

- Perioperative bleeding in cardiac surgery is associated with morbidity and mortality
- Intravenous antifibrinolytics are standard of care: tranexamic acid (TxA)
- Intravenous TxA increases the risk of seizure (neurotoxic)
- Seizure in ICU: stroke protocol alert



Problem

- Catch 22: Anesthesiologists decrease the dose of TxA to prevent seizures but at risk of more bleeding
- No standard dose: 1 to 10 grams
- Giving TxA <u>directly</u> on the source of bleeding (topical) has been tested in various type of surgery
- Promising alternative in our pilot study



Question

- In patients undergoing on-pump cardiac surgery, does topical tranexamic acid (intra-pericardial) compared to the usual intravenous tranexamic acid administration
 - -reduce the risk of in-hospital seizure without increasing red blood cell transfusion?



Design

- Randomized controlled trial
- Double dummy to maintain blinding
- Sample size: 3800 patients
- Funding: Canadian Institute of Health Research



Eligibility criteria

- Included patients
 - ≥18 yrs undergoing cardiac surgery with cardiopulmonary bypass
 - Median sternotomy
- Excluded patients (too low or too high risk of bleeding)
 - Minimally invasive surgery or off-pump CABG
 - Bleeding disorder
 - eGFR <30 ml/min
 - Pre-operative hemoglobin >170 g/L or <110 g/L or thrombocytopenia (<50,000 platelets per μL)
 - Expected circulatory arrest
 - Active endocarditis



Intervention and Follow-up

- Patients randomized to receive
 - TxA 1-10 g IV bolus or placebo at start and during surgery
 - TxA 1-10 g topical or placebo at end of surgery (Protamine)
- Follow-up
 - until discharge or 10 days, whichever occurred first



Outcomes

- Primary outcome
 - Seizure
- Secondary outcome
 - Red blood cell transfusion
- Tertiary outcomes:
 - Blood products transfusion, MACE (death, MI, stroke), reoperation for bleeding or tamponade, ICU length of stay



Enrollment

- Second pre-specified interim analysis by DSMB (75%)
- DSMB recommended to stop the trial for safety
- Operations Committee reviewed the data and stop enrollment in the trial on November 28, 2023
- 3242 patients enrolled out of 3800



Baseline charact	eristics	
	Topical TxA (N=1624)	Intravenous TxA (N=1618)
Age – (mean yrs)	66.3	65.7
Male	77%	78%
History of		
Myocardial infarction	38%	40%
Diabetes	30%	29%
Stroke	4%	4%
Seizure history	0.9%	0.4%
Elective surgery	65%	64%
ACC.2Q	Nº I	

Surgical characteristics

	Topical TxA (N=1624)	Intravenous TxA (N=1618)
CABG only	69%	70%
Valve only	13%	12%
Ascending aorta only	1%	1%
Mixed	16%	15%
CPB time (mins)	88.7	88.6
Cross-clamp time (mins)	66.2	66.0



Compliance and Follow-up

- In both TxA and placebo groups
 - 96.5% of patients received active treatment allocation
- Follow-up: 100% of participants completed



Primary outcome

	Topical TxA n=1624 no. (%)	Intravenous TxA n=1618 no. (%)	RR (95% CI)	P value
Seizure	4 (0.2)	11 (0.7)	0.36 (0.12-1.14)	0.07

• Fisher's exact test



Post Hoc Primary outcome

	Topical TxA	Intravenous TxA	RR	Р
	n=1624	n=1618	(95% CI)	Value
	no. (%)	no. (%)		
Seizure	4 (0.2)	11 (0.7)	0.36 (0.12-1.14)	0.07
Any seizure*	4 (0.2)	14 (0.9)	0.29 (0.09-0.86)	0.02

*patients with seizure and stroke were included



Post Hoc Primary outcome

Stroke	Topical TxA	Intravenous TxA	RR	Р
	n=22	n=12	(95% CI)	value
	no. (%)	no. (%)		
Any seizure	0 (0)	3 (25%)	-	0.04



Post Hoc Primary outcome

	Close chambers	•		Р
	n=2268 no. (%)	n=940 no. (%)	(95% CI)	value
Seizure	7 (0.3)	8 (0.9)	0.36 (0.13-0.99)	0.04
Any seizure	8 (0.4)	10 (1.1)	0.33 (0.13-0.84)	0.01





Secondary outcome

	Topical TxA n=1624 no. (%)	Intravenous TxA n=1618 no. (%)	RR (95% CI)	P value
RBC transfusion	570 (35.1)	433 (26.8)	1.31 (1.18-1.46)	< 0.001

One-side value for non-inferiority P=0.007

ACC

DA

Tertiary outcomes

	Topical TxA	Intravenous TxA	RR
	n=1624	n=1618	(95% CI)
	no. (%)	no. (%)	
Any blood products	756 (46.6)	583 (36.0)	1.29 (1.19-1.40)
Re-op bleeding	63 (3.9)	46 (2.8)	1.37 (0.94-1.98)
ICU LOS (hr) –med	24	24	-
MACE	40 (2.5)	31 (1.9)	1.29 (0.81-2.04)



Intravenous dosage and Outcomes

Intravenous TxAGroupSeizureAny SeizureRBC transfusionn=1618n=no. (%)no. (%)no. (%)

0 to 36mg/kg 612 5 (0.8) 5 (0.8) 164 (26.8) 36.1 to 60mg/kg 621 4 (0.6) 5 (0.8) 154 (24.8) >60.1 mg/kg 355 2 (0.6) 4 (1.1) 110 (31.0)



Subgroup Seizure

A Seizure									
Subgroup	Topical	Intravenous			Ri	sk Ratio	o (95% (CI)	
	no. of events/r	no. of patients (%))						
Age									
<65	2/617 (0.3)	4/665 (0.6)						-	0.54 (0.10 to 2.93)
≥65	2/1006 (0.2)	7/952 (0.7)	—			_			0.27 (0.06 to 1.30)
Sex									
Female	1/375 (0.3)	3/348 (0.9)							0.31 (0.03 to 2.96)
Male	3/1248 (0.2)	8/1270 (0.6)		-					0.38 (0.10 to 1.44)
Surgery rating									
Urgent	1/571 (0.2)	1/578 (0.2)						-	1.01 (0.06 to 16.1)
Elective	3/1052 (0.3)	10/1039 (1.0)							0.30 (0.08 to 1.07)
Type of surgery									
Isolated CABG	2/1127 (0.2)	5/1141 (0.4)							0.41 (0.08 to 2.08)
Isolated valve	2/213 (0.9)	4/193 (2.1)		-					0.45 (0.08 to 2.45)
Isolated ascending aorta	0/16 (0.0)	0/16 (0.0)							
Mixed	0/253 (0.0)	2/249 (0.8)							
			0.0	0.5	1.0	1.5	2.0	2.5	
			4				allen o Tarl		
			Тор	ical Be	tter I	ntraven	ious Bet	tter	



Subgroup RBC transfusion

Subgroup	Topical	Intravenous		Risk Ratio (95%	CI)
		o. of patients (%)			
Age					
<65	168/617 (27.2)	145/665 (21.8)			1.25 (1.03 to 1.52)
≥65	402/1006 (40.0)	288/952 (30.3)			1.32 (1.17 to 1.49)
Sex					
Female	192/375 (51.2)	161/348 (46.3)		- e	1.11 (0.95 to 1.29)
Male	378/1248 (30.3)	272/1270 (21.4)			1.41 (1.24 to 1.62)
Preoperative antiplate	elet				
Yes	360/1060 (34.0)	277/1048 (26.4)			1.29 (1.13 to 1.47)
No	210/564 (37.2)	156/570 (27.4)		_ —	1.36 (1.15 to 1.62)
Surgery rating					
Urgent	237/571 (41.5)	201/578 (34.8)			1.19 (1.03 to 1.38)
Elective	333/1052 (31.7)	232/1039 (22.3)			1.42 (1.23 to1.64)
Type of surgery					
Isolated CABG	361/1127 (32.0)	288/1141 (25.2)			1.27 (1.11 to 1.45)
Isolated valve	68/213 (31.9)	44/193 (22.8)			1.40 (1.01 to 1.94)
Isolated ascending	aorta 3/16 (18.8)	4/16 (25.0)			 0.75 (0.20 to 2.83)
Mixed	136/253 (53.8)	95/249 (38.2)		_ _	1.41 (1.16 to 1.71)
		0	.0 0.5	1.0 1.5 2.0	2.5
					>
			Topical Bette	er Intravenous B	etter




Conclusions of our trial

- Topical TxA does not reduce risk of seizure
- Topical TxA increases the risk of transfusion




How does TxA cross the blood-brain barrier?





Micro-bubbles and Focused ultrasound





Further hypotheses

- Mechanism of seizure is more complex
 - Not likely related to dose of IV TxA
 - Probably mediated by air embolism or debris
 - Presence or absence of TxA at the time of embolism (X-clamp) could be the mechanism to reduce seizure: timing
 - Need for clinically available tests to measure TxA levels and fibrinolysis to improve bleeding



Circulation

• Circulation. 2024; [published online ahead of print]. DOI: 10.1161/CIRCULATIONAHA.124.069606

Topical Versus Intravenous Tranexamic Acid in Patients Undergoing Cardiac Surgery: The DEPOSITION Randomized Controlled Trial

 Andre Lamy, MD, MHSc; Dmitry A. Sirota, MD, PhD; Frederic Jacques, MD, MSc; Ahmad Poostizadeh, MD; Nicolas Noiseux, MD, PhD; Sergey Efremov, MD, PhD; Philippe Demers, MD; Boris Akselrod MD, PhD; Chew Yin Wang, MBChB; Rakesh C. Arora MD, PhD; Piotr Branny, MD; Shay P. McGuinness, MBChB; Craig D. Brown, MD; Hugues Jeanmart, MD; Qiang Zhao, MD; Haibo Zhang, MD, PhD; Emilie P. Belley-Côté, MD, PhD; Richard P. Whitlock, MD, PhD; Austin Browne, MSc, PhD; Ingrid Copland, CCRA; Jessica Vincent, MSc; Rutaba Khatun, MSc; Kumar Balasubramanian, MSc; Shrikant I. Bangdiwala, PhD; Michael H. McGillion, RN, PhD; Alison E. Fox-Robichaud, MD; Jessica Spence, MD, PhD; Salim Yusuf, MD, Dphil; and P.J. Devereaux, MD, PhD for the DEPOSITION Study Group

Circulation


https://www.ahajournals.org/DOI: 10.1161/CIRCULATIONAHA.124.069606



• Thank you.



3242 patients randomized 16 centres in 6 countries



Glycine receptors





Figure 2.4 TXA is a competitive antagonist of glycine receptors.

Glycine and TXA are structural analogues suggesting that TXA competes for the glycine binding site of the glycine receptor.



Tranexamic acid and bleeding



- Tranexamic Acid (TXA) is a synthetic derivative of the amino acid lysine.
 - It has a very high affinity for the lysine binding sites of plasminogen.
 - It blocks these sites and prevents binding of plasmin to the fibrin surface, thus exerting its antifibrinolytic effect.



Statistics

- Primary outcome hypothesis
 - Topical TXA superior to IV TXA for seizure
 - Fisher's exact test with 2-sided P < 0.05
- Secondary outcome hypothesis
 - Topical TXA noninferior to IV TXA for red blood cell transfusion
 - upper bound of 1-sided 97.5% CI for HR needed to fall below 1.15
 - 1-sided P < 0.025



Post Hoc Tertiary outcome



